EMERYVILLE, Calif., Sept. 2, 2015 (GLOBE NEWSWIRE) -- KineMed Inc. today announced that Patrick Doyle, President of KineMed is scheduled to present at the 17th Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2015 in New York, NY.
Details of the presentations are as follows:
|Conference:||Rodman & Renshaw Global Investment Conference|
|Date:||Wednesday, September 9, 2015|
|Time:||3:25 PM, ET|
|Room:||Astor Suite A, Second Floor, St. Regis Hotel, NYC|
Investors attending the conferences who would like to schedule a one-on-one meeting with KineMed's management may do so by contacting their Rodman & Renshaw representatives, or Joseph Green at The Ruth Group at firstname.lastname@example.org.
About KineMed, Inc.
KineMed is a life sciences company that is using its dynamic proteomics platform to develop drugs more efficiently and with less risk. Dynamic proteomics, in a single sample, rapidly detects target engagement, tracks disease progression and provides data that are highly predictive of late-stage success. The previously unavailable molecular biochemistry behind our non-invasive kinetic measurements is based upon the body's metabolic incorporation of safe, non-radioactive tags into newly synthesized molecules through disease-modifying pathways. The rates, or activity, of these disease-modifying metabolic pathways are measured by highly sensitive mass spectrometric analytic techniques. Our technology platform, developed and validated over the past decade, establishes early proof-of-concept, target validation, pharmacodynamics, evidence of toxicity, and optimal dose. We apply our dynamic proteomics platform to our biopharma-partners' drug assets as well as in advancing our own pipeline. For more information, please visit www.KineMed.com.